Lou Berneman is the founding partner in this specialty fund that invests in academic start-ups.
OUP (Osage University Partners) recently announced the closing if its third fund at $273 million, exceeding its target of $250 million. This marks the firm's third fund dedicated to investment exclusively in startups commercializing university research, and the firm’s largest fund to date, bringing OUP’s total assets under management to approximately $600 million. Click here for more information.
Read a March 2014 article in les Nouvelles about Venture Capital: 101 by Lou Berneman.
Lou Berneman is Lead Advisor Non-Profit institutions for this private equity fund producing interests in health care products.
Read a March 2014 article in les Nouvelles about Maximizing the Value of License Agreements by Lou Berneman.
Texelerate assists entrepreneurs and inventors negotiate and craft license and related collaboration agreements.
Exemplary Engagements Include:
InstaRecon, Inc. Bedrock Inventions, LLC• Shareholder Representative Services LLC v. Telenor Digital Holdings Inc. (USA) Arbitration under the United Nations Commission on International Trade Rules
• Roche Diagnostics GmbH v. Enzo Biochem, Inc. US District Court, Case No. 04-cv-4046 (RJS)
• In re Modafinil Litigation Federal Trade Commission v. Cephalon, Inc. European Commission
• Encore Supply Strategies, LLC v. Ernst & Young LLP International Institute for Conflict Prevention & Resolution, CPR File No. G-16-43-C
• Medtronic, Inc. and Consolidated Subsidiaries v. Commissioner of Internal Revenue US Tax Court Docket No. 6944-11
• Solazyme, Inc. v. Roquette Freres, S.A., Abritration
• Enzo Biochem, Inc. and Enzo Life Sciences, Inc., v. PerkinElmer, Inc. and PerkinElmer Life Sciences, Inc., Case No. O3-cv-3817 (RJS), Southern District of New York
• Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. v. Norwell, Inc., Case No. 16 193 Y 0066712
• Gatekeeper Pharmaceuticals, Inc. v. Novartis Pharma, A.G., Civil Action No. 1:10-CV-11613
• SPH America, LLC v. Acer, Inc., et al. Civil Action No. 1:09-CV-740 LMB/JFA
• Apple Inc. v. Motorola Mobility, Inc., Case No. 11-cv-178-bbc
• Lakeland Regional Medical Center, Inc. v. Astellas US, LLC and Astellas Pharma US, Inc. Case No. 8:10cv2008-33TGW
• MedImmune, LCC v. Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. et al., Case No. 351304-V
• The Research Foundation of the State University of New York v. Nektar Therapeutics, Inc., Civil Action No.: 1:09-CV-01292 (GLS) (DRH)
• Apple Inc. and NeXT Software Inc. v. Motorola Inc. and Motorola Mobility, Inc., Case No. 10-CV-662 (BBC)
• Desktop Metal, Inc. v. Markforged and Matiu Parangi US District Court, Civil Action No. 1:18-cv-10524-WGY
• In re Modafinil Litigation, Apotex, Inc. v. Ranbaxy, Inc. US District Court, No. 2:06-cv-2768
• ATM Shafiqul Khalid v. Citrix Systems, Inc. Superior Court in the State of Washington, No. 15-2-24309-8 SEA
• Children’s Medical Center Corporation and CV Rev Holdings LLC v Celgene Corporation US District Court, C.A. No. 13-CV-11573-MLW-JGD
• Yeda Research and Development Company, Ltd. v UCB, Inc. US District Court, Case No. 1:14-cv-1038-LMB-TCB
• SkinMedica, Inc. v. Histogen, Inc. et al, Case No. CV 09-0122 JLS (NLS)
• King Drug Company of Florence, Inc., et al. v. Cephalon, Inc. et al., Civil Action No. 06-cv-1797
• In the matter of Certain Mobile Devices, Associated Software, and Components Thereof, Investigation No. 337-TA-744, United States International Trade Commission (Microsoft v. Motorola)
• Emory University and University of Georgia Research Foundation, Inc. v. Pharmasset, Inc., Case No. 30 122 Y 00596 09 before American Arbitration Association, Atlanta, Georgia
• Enanta Pharmaceuticals, Inc. v. Abbott Laboratories (Arbitration)
• St. Clair Intellectual Property Consultants, Inc., v. Research in Motion Ltd. et al., Research in Motion Corp Civil Action No. 08-371-JJF-LPS
• City of Hope National Medical Center v. Genentech, Inc. B161549 Los Angeles County Super. Ct. No. BC215152
• Kourosh A. Dastgheib v. Genentech, Inc. Civil Action No. 2:04cv1283
• Frederic A. Stern v. The Trustees of Columbia University in the City of New York and Laszlo Z. Bito, Civil Action No. 01 19086 (RCC)
Dr. Berneman, an intellectual property business development expert, serves as managing director of Texelerate, LLC, a technology transfer consultancy focused on financing startup ventures, monetizing royalties, and negotiating patent license and related alliance agreements. He has valued, structured, negotiated, drafted, and monitored hundreds of intellectual property license agreements in the life sciences and tech sectors. He also has extensive experience testifying on licensing and damages issues in federal and state courts and in arbitration. Dr. Berneman is a Certified Licensing Professional (CLP) and a Registered Technology Transfer Professional (RTTP).
Dr. Berneman is the founding partner of Osage University Partners (OVP.VC), a venture fund. He is also a senior advisor to HealthCare Royalty Partners, a private investment fund, which purchases royalty interests and uses debt-like structures to invest in healthcare products.
He is a past President and long-time Board member of the Association of University Technology Managers (AUTM) and a former Vice President and long-time Trustee of the Licensing Executives Society U.S.A. & Canada (LES). For both AUTM and LES, he developed, chaired, and served on the faculty of their professional development training programs. In 2005, the LES Foundation awarded him the Frank Barnes Mentor Award, presented annually to an LES member who “has dedicated considerable time and energy to mentoring fellow licensing professionals.”
View Louis Berneman's CV.